DBVT · Insider trading · 13F holders · Congress trades
Dbv Technologies S A (DBVT)
Who is buying and selling DBVT: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 12
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $0
- Congress trades, 12 months
- 0
DBVT at a glance
- No open-market insider purchases or sales of DBVT were filed in the last 90 days.
- 12 13F filers hold DBVT among their 50 largest positions, worth $206.8M combined, including Joseph Edelman. The biggest bets by portfolio weight are Mpm Bioimpact LLC (3.7%), Vivo Capital, LLC (2.8%) and Patient Square Capital LP (2.3%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
- No member of Congress has disclosed a trade in DBVT.
DBVT insider trading
No open-market insider purchases or sales of DBVT were filed in the last 90 days.
Who owns DBVT? Hedge funds and superinvestors
12 13F filers hold DBVT among their 50 largest positions, worth $206.8M combined, including Joseph Edelman. The biggest bets by portfolio weight are Mpm Bioimpact LLC (3.7%), Vivo Capital, LLC (2.8%) and Patient Square Capital LP (2.3%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
Superinvestors holding DBVT: Joseph Edelman 0.4%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Mpm Bioimpact LLCHedge fund | 3.7% | $60.1M | 3,666,284 | -29.7% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 0.6% | $30.5M | 1,857,362 | +0.0% shares | Q2 2026 |
| Vivo Capital, LLCHedge fund | 2.8% | $30.3M | 1,844,758 | -30.8% shares | Q2 2026 |
| Joseph EdelmanHedge fund | 0.4% | $27.1M | 1,653,350 | — | Q2 2026 |
| Logos Global Management LPHedge fund | 0.6% | $15.0M | 915,000 | — | Q2 2026 |
| Patient Square Capital LPHedge fund | 2.3% | $14.9M | 909,474 | +31.1% shares | Q2 2026 |
| Octagon Capital Advisors LPHedge fund | 0.9% | $9.4M | 574,200 | +0.0% shares | Q2 2026 |
| Redmile Group, LLCHedge fund | 0.5% | $6.7M | 410,440 | -16.5% shares | Q2 2026 |
| Elmind Capital, LPHedge fund | 1.1% | $4.3M | 265,000 | +0.0% shares | Q2 2026 |
| Ishara Investments LPHedge fund | 2.2% | $3.0M | 184,500 | +80.0% shares | Q2 2026 |
| Yiheng Capital Management, L.P.Hedge fund | 1.2% | $2.8M | 170,142 | +0.0% shares | Q2 2026 |
| Great Point Partners LLCHedge fund | 0.6% | $2.6M | 156,906 | New | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 12). Screen DBVT in the grand portfolio →
DBVT stock trades by members of Congress
No member of Congress has disclosed a trade in DBVT.
DBVT questions and answers
Are insiders buying DBVT stock?
No open-market insider purchases or sales of DBVT were filed in the last 90 days.
Which hedge funds own DBVT?
12 13F filers hold DBVT among their 50 largest positions, worth $206.8M combined, including Joseph Edelman. The biggest bets by portfolio weight are Mpm Bioimpact LLC (3.7%), Vivo Capital, LLC (2.8%) and Patient Square Capital LP (2.3%). In their latest 13Fs, 1 manager opened a new position and 2 added to one.
Has Congress traded DBVT?
No member of Congress has disclosed a trade in DBVT.
Who is the largest holder of DBVT?
Among 13F filers, Mpm Bioimpact LLC reports the largest DBVT position, $60.1M (3,666,284 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Mpm Bioimpact LLC's: 3.7% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.